Does early insulin treatment decrease the risk of microangiopathy in non-obese adults with diabetes?

Archives of Medical Science

Volumn 3, Issue 2, 2007, Pages 129-135

  Rogowicz, Anita ^a   Litwinowicz, Monika ^a   Piłaciński, Stanisław ^a   Zozulińska, Dorota ^a   Wierusz Wysocka, Bogna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Latent autoimmune diabetes in the adults; Microangiopathy; Treatment of diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE DURATION; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; OBESITY; RISK FACTOR; SMOKING;

EID: 34547814203     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Naik R, Palmer J. Latent autoimmune diabetes in adults. Rev Endocr Metab Disord 2003; 4: 233-41.
2. Groop L, Toumi T, Rowley M. Latent autoimmune diabetes in adults (LADA) - more than a name. Diabetologia 2006; 49: 1996-8.
3. Maruyama T, Shimada A, Kanatsuka A, et al. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo Study): preliminary report. Ann NY Acad Sci 2003; 1005: 362-9.
4. Kobayashi T, Nakanishi K, Murase T. Small doses of subcutaneous insulin as strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622-6.
5. Stenström G, Gottsäter A, Bakhtadze E, Barger B, Sundkvist G. Latent Autoimmune Diabetes in Adults: definition, prevalence, [beta]-cell function, and treatment. Diabetes 2005; 54: 68-72.
6. Bell DS, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. Am J Ther 2004; 11: 308-11.
7. Kuruca P, Novakova B, Behanova M, Novak J, Tlaskova-Hogenova H, Andel M. Gliadin, endomysial and thyroid autoantibodies in patients with latent autoimmune diabetes in adults (LADA). Clin Exp Immunol 2003; 133: 139-43.
8. DCCT Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
9. EDIC Research Group: Epidemiology of Diabetes Interventions and Complications Trial (EDIC). Design, implementation, and preliminary results of long-term follow-up of the Diabetes Control and Complication Trial cohort. Diabetes Care 1999; 22: 99-111.
10. Stratton IM, Adler AI, Nail HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
11. Porta M, Sjoelie AK, Chaturvedi N, et al. EURODIAB Prospective Complications Study Group. Risk factor for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001; 44: 2203-9.
12. Adler AI, Stratton IM, Nail HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observation study. BMJ 2000; 321: 412-19.
13. Pozzilli P, Di Mario U. Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24: 1460-7.
14. Szepietowska B, Szelachowska M, Kinalska I. Do Latent Autoimmune Diabetes of the Adult (LADA) Patients Require Insulin at Diagnosis? Diabetes Care 2002; 25: 1662-3.
15. 15.Arikan E, Sabuncu T, Ozer E, Hatemi H. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with type 2 diabetes. J Diabetes Complications 2005; 19: 245-8.
16. Balme M, McAllister I, Davis WA, Davis TM. Retinopathy in latent autoimmune diabetes of adults: the Fremantle Diabetes Study. Diabet Med 2002; 19: 602-5.
17. Isomaa B, Tuomi T, Almgren P, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22: 1347-53.
18. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular micropartides. Diabetes 2002; 51: 2840-5.
19. Chiu HK, Tsai EC, Juneja R, et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 237-44.
20. Li X, Zhou ZG, Yang L, Huang G, Yan X. Metabolic syndrome and latent autoimmune diabetes in adults. Zhonguo Yi Xue Ke Xue Yuan Xue Bao 2003; 25: 676-9.
21. Wildasin EM, Skaar DJ, Kirchain WR, Hulse M. Metformin, a promising oral antihyperglycemic for treatment of noninsulin-dependent diabetes mellitus. Pharmacotherapy 1997; 17: 62-73.
22. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonyureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical complication. Diabetes Metab 2003; 29: 207-22.
23. Peuler JD, Miller JA, Bourghli M, Zammam HY, Soltis EE, Sowers JR. Disparte effects of antidiabetic drugs on arterial contraction. Metabolism 1997; 46: 1199-1205.